314 related articles for article (PubMed ID: 20371460)
1. Biotechnology: delivering on the promise.
Greenwood JC
Sci Transl Med; 2010 Jan; 2(13):13cm1. PubMed ID: 20371460
[TBL] [Abstract][Full Text] [Related]
2. A venture capital view of challenges, opportunities, and innovation in biomedical research.
Ratcliffe LT
Clin Pharmacol Ther; 2011 Feb; 89(2):174-6. PubMed ID: 21252935
[TBL] [Abstract][Full Text] [Related]
3. Basic and applied research in India: present and future.
Ramasami T; Rao AV; Natesh S
Biotechnol J; 2009 Mar; 4(3):301-5. PubMed ID: 19296436
[No Abstract] [Full Text] [Related]
4. What's fueling the biotech engine?
Aggarwal S
Nat Biotechnol; 2007 Oct; 25(10):1097-104. PubMed ID: 17921989
[No Abstract] [Full Text] [Related]
5. Industrial health research in Canada.
Morin Y
CMAJ; 2007 Jun; 176(12):1734; author reply 1734. PubMed ID: 17548390
[No Abstract] [Full Text] [Related]
6. Supporting the work of lesser geniuses: an argument for removing obstructions to human embryonic stem cell research.
Hazuka CD
Univ Miami Law Rev; 2002 Oct; 57(1):157-220. PubMed ID: 15156896
[No Abstract] [Full Text] [Related]
7. Perspective: A tale of 'cautious pessimism': Biotechnology, recession and the 'new economy'.
Kewell B; Webster A
Biotechnol J; 2009 Aug; 4(8):1106-8. PubMed ID: 19685467
[No Abstract] [Full Text] [Related]
8. The promise of South African biotech.
Akermann B; Kermani F
Drug Discov Today; 2006 Nov; 11(21-22):962-5. PubMed ID: 17055404
[No Abstract] [Full Text] [Related]
9. Japanese council urges reform of funding system.
Triendl R
Nat Biotechnol; 2002 Dec; 20(12):1176-8. PubMed ID: 12454656
[No Abstract] [Full Text] [Related]
10. Democracy unleashed--unpacking the tooth fairy in drug industry R&D.
Ozdemir V; Williams-Jones B
Nat Biotechnol; 2006 Nov; 24(11):1324-6; author reply 1326-7. PubMed ID: 17093467
[No Abstract] [Full Text] [Related]
11. Research interactions between industry and academia: a corporate perspective.
Citron P
Physiologist; 1996 Jun; 39(3):81, 90-2. PubMed ID: 16764116
[No Abstract] [Full Text] [Related]
12. Comparative effectiveness casts first shadows across US industry.
Waltz E
Nat Biotechnol; 2009 Mar; 27(3):211-2. PubMed ID: 19270651
[No Abstract] [Full Text] [Related]
13. Deal watch: Trends in platform technology deal-making.
Walker J; Jacob J
Nat Rev Drug Discov; 2009 Dec; 8(12):923. PubMed ID: 19949395
[No Abstract] [Full Text] [Related]
14. Stealth merger: drug companies and government medical research.
Willman D
Los Angeles Times; 2003 Dec; ():A1, A32-3. PubMed ID: 14971391
[No Abstract] [Full Text] [Related]
15. Australia's bio-regulatory framework: leading the way for stem cell research.
Hill H
J Biolaw Bus; 2004; 7(2):61-4. PubMed ID: 15460561
[TBL] [Abstract][Full Text] [Related]
16. Gold in the ivory tower: equity rewards of outlicensing.
Edwards M; Murray F; Yu R
Nat Biotechnol; 2006 May; 24(5):509-15. PubMed ID: 16680129
[TBL] [Abstract][Full Text] [Related]
17. The biotechnology industry: What's next?
Guertin PA
Biotechnol J; 2009 Aug; 4(8):1124-31. PubMed ID: 19685466
[No Abstract] [Full Text] [Related]
18. Overcoming the challenges in the pharma/biotech industry.
Graul AI; Prous JR
Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
[TBL] [Abstract][Full Text] [Related]
19. University-industry collaboration. Last of the big-time spenders?
Lawler A
Science; 2003 Jan; 299(5605):330-3. PubMed ID: 12531991
[No Abstract] [Full Text] [Related]
20. The attitudes of religious, environmental, and science policy leaders toward biotechnology.
Miller JD
Recomb DNA Tech Bull; 1985 Dec; 8(4):141-64. PubMed ID: 4095277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
